[1. Bittner V. Menopause, age, and cardiovascular risk: a complex relationship. J Am Coll Cardiol. 2009; 54(25):2374–5.10.1016/j.jacc.2009.10.00820082926]Search in Google Scholar
[2. Magnani JW, Moser CB, Murabito JM, et al. Age of natural menopause and atrial fibrillation: the Framingham Heart Study. Am Heart J. 2012; 163(4):729–34. 3 Vaidya D, Becker DM,10.1016/j.ahj.2012.01.010333486122520541]Search in Google Scholar
[3. Bittner V, Mathias RA, Ouyang P. Ageing, menopause, and ischaemic heart disease mortality in England, Wales, and the United States: modelling study of national mortality data. BMJ. 2011; 343:d5170.10.1136/bmj.d5170316716421896608]Search in Google Scholar
[4. Malkin CJ, Pugh PJ, Jones RD, Jones TH, Channer KS. Testosterone as a protective factor against atherosclerosis--immunomodulation and influence upon plaque development and stability. J Endocrinol. 2003; 178(3):373–80.10.1677/joe.0.178037312967330]Search in Google Scholar
[5. Phillips GB. Is atherosclerotic cardiovascular disease an endocrinological disorder? The estrogen-androgen paradox. J Clin Endocrin Metab. 2005; 90(5):2708-2711.10.1210/jc.2004-201115687329]Search in Google Scholar
[6. Burke A.P., Farb A., Malcom G., Virmani R.. Effect of menopause on plaque morphologic characteristics in coronary atherosclerosis, Am Heart J, 2001; vol. 141 2:58-62.10.1067/mhj.2001.10994611174360]Search in Google Scholar
[7. Rossouw JE, Prentice PL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007; 297(13):1465-1477.10.1001/jama.297.13.146517405972]Search in Google Scholar
[8. Peter I, Kelley-Hedgepeth A, Huggins GS, et al. Association between arterial stiffness and variations in oestrogen-related genes. J Hum Hypertens. 2009; 23(10):636-644.10.1038/jhh.2009.1274626019194457]Search in Google Scholar
[9. Debing E, Peeters E, Duquet W, Poppe K, Velkeniers B, Van den Brande P. Endogenous sex hormone levels in postmenopausal women undergoing carotid artery endarter-ectomy. Eur J Endocrinol. 2007; 156(6):687-69310.1530/EJE-06-070217535869]Search in Google Scholar
[10. Austin C.E.. Chronic and acute effects of oestrogens on vascular contractility, J Hypertens, 2000, vol. 18:1365-1378.10.1097/00004872-200018100-0000311057423]Search in Google Scholar
[11. HigashiY., Sanada M., Sasaki S., et al. Effect of estrogen replacement therapy on endothelial function in peripheral resistance arteries in normotensive and hypertensive postmenopausal women, Hypertension, 2001; vol. 37:651-657.10.1161/01.HYP.37.2.651]Search in Google Scholar
[12. Bechlioulis A, Naka KK, Calis KA, et al. Cardiovascular Effects of Endogenous Estrogen and Hormone Therapy. Curr Vasc Pharmacol. 2010; 8:249-258.10.2174/15701611079088697419485910]Search in Google Scholar
[13. Badimon, L. New challenges in the etiopathogenesis of atherothrombosis. Cerebrovasc Dis 11 Suppl 1. 2001;80-84.10.1159/00004912911244204]Search in Google Scholar
[14 Hodges Y.K., Tung L., Yan X.D., Graham J.D., Horwitz K.B., Horwitz L.D..Estrogen receptors alpha and beta: prevalence of estrogen receptor beta mRNA in human vascular smooth muscle and transcriptional effects. Circulation, 2000; vol.101:1792-1798.10.1161/01.CIR.101.15.179210769279]Search in Google Scholar
[15. Shearman AM, Cooper JA, Kotwinski PJ, et al. Estrogen receptor alpha gene variation is associated with risk of myocardial infarction in more than seven thousand men from five cohorts. Circ Res. 2006; 98(5):590-592.10.1161/01.RES.0000210578.62102.a616484614]Search in Google Scholar
[16. Hodges YK, Tung L, Yan XD, Graham JD, Horwitz KB, Horwitz LD. Estrogen receptors alpha and beta: prevalence of estrogen receptor beta mRNA in human vascular smooth muscle and transcriptional effects. Circulation. 2000; 101(15):1792-1798.10.1161/01.CIR.101.15.1792]Search in Google Scholar
[17. Schuit SC, Oei HH, Witteman JC, et al. Estrogen receptor alpha gene polymorphisms and risk of myocardial infarction. JAMA. 2004; 291(24):2969-2977.10.1001/jama.291.24.296915213208]Search in Google Scholar
[18. Schuit SC, de Jong FH, Stolk L, et al. Estrogen receptor alpha gene polymorphisms are associated with estradiol levels in postmenopausal women. Eur J Endocrinol. 2005; 153(2):327-334.10.1530/eje.1.0197316061840]Search in Google Scholar
[19. Malkin CJ, Pugh PJ, Jones RD, Jones TH, Channer KS. Testosterone as a protective factor against atherosclerosis--immunomodulation and influence upon plaque development and stability. J Endocrinol. 2003; 178(3):373–80.10.1677/joe.0.178037312967330]Search in Google Scholar
[20. Liu PY, Death AK, Handelsman DJ. Androgens and cardio-vascular disease. Endocr Rev. 2003; 24(3):313-340.10.1210/er.2003-000512788802]Search in Google Scholar
[21. Yeap BB, Hyde Z, Almeida OP, et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab. 2009; 94(7):2353-2359.10.1210/jc.2008-2416]Search in Google Scholar
[22. Gonzalez-Clemente JM, Gimenez-Palop O, Vilardell C, Caixas A, Gimenez-Perez G. Are statins analogues of vitamin D? Lancet. 2006; 368(9543):1233.10.1016/S0140-6736(06)69507-X]Search in Google Scholar
[23. Perez-Castrillon JL, Vega G, Abad L, et al. Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol. 2007; 99(7):903-905.10.1016/j.amjcard.2006.11.03617398180]Search in Google Scholar
[24. Michos ED, Melamed ML. Vitamin D and cardiovascular disease risk. Curr Opin Clin Nutr Metab Care. 2008; 11(1):7-12.10.1097/MCO.0b013e3282f2f4dd18090651]Search in Google Scholar
[25. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men:a prospective study. Arch Intern Med. 2008; 168(11):1174-1180.10.1001/archinte.168.11.1174371939118541825]Search in Google Scholar
[26. Pilz S, Dobnig H, Nijpels G, et al. Vitamin D and mortality in older men and women. Clin Endocrinol (Oxf). 2009; 71(5):666-672.10.1111/j.1365-2265.2009.03548.x19226272]Search in Google Scholar
[27. Wannamethee SG, Tchernova J, Whincup P, et al. Plasma leptin: associations with metabolic, inflammatory and haemostatic risk factors for cardiovascular disease. Atherosclerosis. 2007; 191(2):418-426.10.1016/j.atherosclerosis.2006.04.01216712853]Search in Google Scholar
[28. Wolk R, Berger P, Lennon RJ, Brilakis ES, Johnson BD, Somers VK. Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol. 2004; 44(9):1819-1824.10.1016/j.jacc.2004.07.05015519013]Search in Google Scholar
[29. Kizer J, Barzilay JI, Kuller LH, Gottdiener JS. Adiponectin and risk of coronary heart disease in older men and women. J Clin Endocrin Metab. 2008; 93(9):3357-3364.10.1210/jc.2008-0640256785318593765]Search in Google Scholar
[30. Butler J, Kalogeropoulos A, Georgiopoulou V, et al, for the Health ABC Study. Serum resistin concentrations and risk of new onset heart failure in older persons: the health, aging, and body composition (Health ABC) study. Arterioscler Thromb Vasc Biol. 2009; 29(7):1144-1149.10.1161/ATVBAHA.109.186783275729019372460]Search in Google Scholar
[31. Frankel DS, Vasan RS, D’Agostino RB Sr, et al. Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J Am Coll Cardiol. 2009; 53(9):754-762.10.1016/j.jacc.2008.07.073267679319245965]Search in Google Scholar
[32. Bonaa K, Njolstad I, Ueland P. NORVIT trial investigators. Homocysteine lowering and cadiovascular evens after acute myocardial infarction. N Engl J Med. 2006; 354(15):1578-1588.10.1056/NEJMoa05522716531614]Search in Google Scholar
[33. Shi RZ, Wang JC, Huang SH, Wang XJ, Li QP. Angiotensin II induces vascular endothelial growth factor synthesis in mesenchymal stem cells. Exp Cell Res. 2009; 315(1):10-15.10.1016/j.yexcr.2008.09.02418973754]Search in Google Scholar
[34. Shan H, Bai X, Chen X. Angiotensin II induces endothelial cell senescence via the activation of mitogen-activated protein-kinases. Cell Biochem Funct. 2008; 26(4):459-466.10.1002/cbf.146718383564]Search in Google Scholar
[35. Javeshghani D, Sairam MR, Neves MF, Schiffrin EL, Touyz RM. Angiotensin II induces vascular dysfunction without exacerbating blood pressure elevation in a mouse model of menopause-associated hypertension. J Hypertens. 2006; 24(7):1365-1373.10.1097/01.hjh.0000234117.25401.f816794486]Search in Google Scholar
[36. Vinh A, Widdop RE, Drummond GR, Gaspari TA. Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice. Cardiovasc Res. 2008; 77(1):178-187.10.1093/cvr/cvm02118006471]Search in Google Scholar
[37. Sluimer JC, Gasc JM, Hamming I, et al. Angiotensin-converting enzyme 2 (ACE2) expression and activity in human carotid atherosclerotic lesions. J Pathol. 2008; 215(3):273-279.10.1002/path.235718498093]Search in Google Scholar
[38. Jacoby DS, Rader DJ. Renin-angiotensin system and atherothrombotic disease: from genes to treatment. Archives o f Internal Medicine. 2003; 163(10):1155–1164.10.1001/archinte.163.10.115512767951]Search in Google Scholar
[39. Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. Journal of Internal Medicine. 2008; 264(3):224–236.10.1111/j.1365-2796.2008.01981.x716693018793332]Search in Google Scholar
[40. Toko H, Zou Y, Minamino T, Masaya M, Harada M, Nagai T, Sugaya T, Terasaki F, Kitaura Y, Komuro I. Angiotensin II type 1a receptor is involved in cell infiltration, cytokine production, and neovascularization in infarcted myocardium. Arterioscler Thromb Vasc Biol. 2004; 24:664–670.10.1161/01.ATV.0000122361.63827.ab14962948]Search in Google Scholar
[41. Singh VP, Le B, Khode R, Baker KM, Kumar R. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes. 2008; 57(12):3297–3306.10.2337/db08-0805]Search in Google Scholar
[42. Singh VP, Baker KM, Kumar R. Activation of the intracellular reninangiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production. American Journal of Physiology. 2008; 294(4):H1675–H1684.10.1152/ajpheart.91493.2007]Search in Google Scholar
[43. Kumar R, Singh VP, Baker KM. The intracellular reninangiotensin system: implications in cardiovascular remodeling. Current Opinion in Nephrology and Hypertension. 2008; 17(2):168–173.10.1097/MNH.0b013e3282f521a8]Search in Google Scholar
[44. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Reninangiotensin system and cardiovascular risk. The Lancet. 2007; 369(9568):1208–1219.10.1016/S0140-6736(07)60242-6]Search in Google Scholar
[45. Connell JM, MacKenzie SM, Freel EM, Fraser R, Davies E. A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr Rev. 2008; 29(2):133-154.10.1210/er.2007-003018292466]Search in Google Scholar
[46. Francis GS, Tang WH. Should we consider aldosterone as the primary screening target for preventing cardiovascular events? J Am Coll Cardiol. 2005; 45:1249-1250.]Search in Google Scholar
[47. Stowasser M. New perspectives on the role of aldosterone excess in cardiovascular disease. Clin Exp Pharmacol Physiol. 2001; 28:783-791.10.1046/j.1440-1681.2001.03523.x11553016]Search in Google Scholar
[48. Marney, A. M., and Brown, N. J. Aldosterone and end-organ damage. Clin. Sci. (Lond.) 2007; 113:267–278.]Search in Google Scholar
[49. Turgeon J, McDonnell D, Martin K, Wise P. Hormone therapy: physiological complexity belies therapeutic simplicity. Science. 2004; 304(5676):1269-1273.10.1126/science.109672515166356]Search in Google Scholar
[50. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007; 356(25):2591-2602.10.1056/NEJMoa07151317582069]Search in Google Scholar
[51. Rossouw JE, Prentice PL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007; 297(13):1465-1477.10.1001/jama.297.13.146517405972]Search in Google Scholar
[52.Herrington D.M., Reboussin D.M., Brosnihan K.B., et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis, N Engl J Med. 2000; vol. 343:522 -529.10.1056/NEJM20000824343080110954759]Search in Google Scholar
[53. Manson JE, Allison MA, Rossouw JE, et al, Estrogen therapy and coronary-artery calcification. N Eng J Med. 2007; 365:2591-2602.]Search in Google Scholar
[54. Tanis BC, V M, Kemmeren JM, Cats VM, Helmerhorst FM, Algra A, Van Der Graaf Y, Rosendaal FR. Oral Contraceptives and the Risk of Myocardial Infarction. N Engl J Med. 2001; 345:1787–93.10.1056/NEJMoa003216]Search in Google Scholar
[55. Lidegaard O. Smoking and use of oral contraceptives: impact on thrombotic diseases. Am J Obstet Gynecol. 1999; 180:S357–63.10.1016/S0002-9378(99)70696-4]Search in Google Scholar
[56. Mitchell, J.H. et al. Antioxidant efficacy of phytoestrogens in chemical and biological model systems. Arch Biochem Biophys. 1998; 360:142-148.10.1006/abbi.1998.09519826439]Search in Google Scholar
[57. Kirk, E.A. et al. Dietary isoflavones reduce plasma cholesterol and atherosclerosis in C57BL/6 mice but not LDL receptor-deficient mice. J Nutr. 1998; 128, 954-959.]Search in Google Scholar
[58. Anthony, M.S., Clarkson, T.B. and Williams, J.K. Effects of soy isoflavones on atherosclerosis: potential mechanisms. Am J Clin Nutr. 1998; 68, 1390S-1393S.10.1093/ajcn/68.6.1390S9848505]Search in Google Scholar